Dengue Fever

Despite considerable efforts, dengue fever remains a major public health challenge, with an estimated 390 million infections occurring annually. Vector control, including the elimination of mosquito breeding sites and the use of insecticides, is the primary preventive measure. However, challenges such as insecticide resistance, climate change, and urbanization complicate control efforts. The development of a dengue vaccine, such as Dengvaxia, has offered a significant breakthrough, although its implementation faces logistical and cost-related hurdles. Vector-modification strategies, like the release of genetically modified mosquitoes, are also being explored. Moreover, advancements in diagnostics and antiviral drug development are ongoing. Integrated, multidisciplinary approaches involving community engagement, surveillance, and improved healthcare infrastructure are essential for effective dengue prevention and control. Continued research and global collaboration are critical for addressing the complexities of dengue transmission and developing sustainable strategies to reduce the burden of this arboviral infection.